Shares of Heron Therapeutics Inc. (Nasdaq:HRTX) rallied strongly up to $0.895/share (+65.74%) at the early session high after traders were able to digest the financial information. This move goes hand in hand with the massive uplift the biotech sector has gotten over the last few months.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company’s product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011.
Copyright © 2023 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com’s content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
]]>